Cell Signaling & Oncology
The signaling pathways controlling cell growth and differentiation are almost invariably altered in cancer. During the course of tumor progression, cancer cells acquire a number of characteristic alterations. These include the capacities to proliferate independently of exogenous growth-promoting or growth-inhibitory signals, to invade surrounding tissues and metastasize to distant sites, to elicit an angiogenic response, and to evade mechanisms that limit cell proliferation, such as apoptosis and replicative senescence. These properties reflect alterations in the cellular signaling pathways that in normal cells control cell proliferation, motility, and survival. These interconnected pathways are being deciphered, but understanding the alterations that lead to cancer and correcting them is a substantial challenge. Among the key pathways are those controlling cell proliferation, which coordinate a response to the cellular environment, with the mTOR kinase as a critical node. Tumour development is influenced by infections and inflammation, and the complex role of the nuclear factor-B transcription factors is being unravelled. Expansion of tumour cells depends on nutrient supply and vascularization, which is orchestrated by the transcription factor known as HIF. And the metastatic spread of primary tumours to other organs is facilitated by many signaling pathways[1],[2].
Cell Signaling and Oncology products Library
For your convenience, you can order a library of all of our Cell Signaling and Oncology research related products. Make your personal library by cherry picking products of your interest from our comprehensive list (>800 products), or order all together not to miss any. The libraries will be shipped as 10 mM solutions (in DMSO, 250 µL of each selected Axon Ligand™) on a 96-well microtiter plate with a clear map of its contents.
Simply download our comprehensive list of epigenetics products below (Microsoft Excel (.xls)), check the products to be included, and return your list to order the library of your preference.
 Axon 5051 - Cell signaling and Oncology Library.xls |
|
[1] A. Eccleston, R. Dhand. Signalling in cancer. Nature 441, 423, editorial note
[2] G.S. Martin. Cell signaling and cancer. Cancer Cell. 2003 Sep;4(3):167-74.
| Axon ID | Name | Description | From price | |
|---|---|---|---|---|
| 2445 | ZLN 024 | Allosteric activator of AMP-activated protein kinase (AMPK) | €90.00 | |
| 2120 | Wnt agonist 1 | Wnt/β-catenin signaling pathway agonist or activator | €90.00 | |
| 2240 | TEPP-46 | Potent activator of recombinant PKM2 with little or no activity versus PKM1, PKL and PKR. | €90.00 | |
| 1875 | SRT 1720 tetrahydrochloride | Activator of the sirtuin subtype SIRT1 | €95.00 | |
| 2084 | SKL 2001 | Wnt/β-catenin signaling pathway agonist or activator | €90.00 | |
| 2244 | SCH 529074 | Small molecule activator of mutant p53. | €120.00 | |
| 2507 | SC 79 | Unique specific activator of cytosolic Akt; neuroprotective | €75.00 | |
| 3954 | SBI-797812 | Orally active NAMPT activator | €130.00 | |
| 4268 | Rezatapopt | First-in-class p53 reactivator | Recently added | Inquire |
| 3480 | PY-60 | Specific YAP activator targeting ANXA2 | €150.00 | |
| 1659 | PS 48 | Allosteric activator of phosphoinositide-dependent protein kinase 1 (PDPK1) | €80.00 | |
| 1743 | PAC 1 | Procaspase activating compound 1 | €80.00 | |
| 3581 | ONC212 | TRAIL inducer; Selective GPR132 agonist | €110.00 | |
| 2497 | Omaveloxolone | Triterpenoid activator of NRF2 and inhibitor of NF-κB | €90.00 | |
| 2564 | NSC 59984 | Activator of p53 that restores WT p53 signaling via p73 activation | €95.00 | |
| 2016 | NSC 319726 | Reactivator of the p53 mutant p53R175 | €95.00 | |
| 2955 | NSC 228155 | EGFR tyrosine kinase activator; Inhibitor of KIX-KID interaction | €75.00 | |
| 2565 | N106 | Activator of E1 ligase mediated SERCA2a SUMOylation | €95.00 | |
| 1941 | MLR 1023 | Selective allosteric activator of Lyn kinase | €95.00 | |
| 2703 | ML346 | Hsp70 activator | €125.00 | |
| 2641 | ML334 | Activator of NRF2 by inhibition of Keap1-NRF2 interactions | €130.00 | |
| 2149 | Mitapivat |
Activator of pyruvate kinase isoenzyme M2 (PKM2) |
€110.00 | |
| 2425 | MHY 1485 | mTOR activator with an inhibitory effect on autophagy | €70.00 | |
| 2484 | K6PC-5 | SphK1 (or SK1) activator that increases sphingosine-1-phosphate production | €105.00 | |
| 2021 | HL 010183 | Metformin derivative; AMPK activator | €135.00 | |
| 3262 | HEI3090 | Positive modulator of the P2X7 receptor | €130.00 | |
| 2264 | Forskolin | Activator of adenylate cyclase. Naturally occurring labdane diterpene | €90.00 | |
| 2300 | Dordaviprone | Small molecule that transcriptionally induces TRAIL | €120.00 | |
| 2841 | COTI-2 | Reactivator of mutant p53 | €125.00 | |
| 1835 | CK 1827452 | Cardiac specific myosin ATPase activator | €115.00 | |